Biosensors International is celebrating a year of significant achievement with an expanded product portfolio, offering physicians a broader range of treatment options to improve patient outcomes.

Since TCT 2012, the company has revitalized its core offering with the launch of BioMatrix NeoFlex(tm), a DES with exceptional performance in complex lesions and challenging anatomies; expanded its range of dedicated bifurcation stents with Axxess(tm) 4.0x9, designed to treat larger, shorter and wider-angulated bifurcations; complemented its stent portfolio by introducing a range of drug-eluting balloon dilation catheters for the treatment of both coronary and peripheral artery disease; and re-established its leadership in coronary stent technology with the introduction of BioFreedom(tm), the world's first polymer-free stent coated with Biolimus A9(tm).

In May 2013 Biosensors took a significant step towards revolutionizing patient care with the acquisition of functional imaging company Spectrum Dynamics, whose expertise will help cath labs determine which patients require a stent without the need for diagnostic angiography. Spectrum Dynamics's technology is faster than conventional functional imaging, requires less contrast medium to be injected, and can deliver up to 10 times the sensitivity and twice the spatial resolution.

"We have come further than we could possibly have imagined since last year's TCT", commented Jeffrey B. Jump, President of Biosensors' Cardiovascular Division. "Over the last twelve months we have revamped the leading biodegradable polymer DES, increased the applications for our specialist bifurcation stent, offered cath labs a wider choice of treatment options with a range of drug-eluting balloons and acquired technology with the potential to fundamentally change the way that interventional cardiology is practiced: so who knows what we can achieve over the next twelve months!"

Visitors to TCT can find full details on Biosensors' expanded portfolio at Booth 1607 in Hall B.